A phase 1/2 study of talazoparib (BMN 673), an oral poly(ADP-ribose) polymerase inhibitor, plus temozolomide in children with refractory or recurrent malignancies: A Children's Oncology Group phase 1 consortium study (ADVL1411)
Year: 2016
Type: article
Source: European Journal of Cancer
Authors: E.S. Schafer, R.E. Rau, X. Liu, C.G. Minard, J.M. Reid, E. Fox, B.J. Weigel, S.M. Blaney
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2560510769